Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion

Diabetes Technology and Therapeutics

Volumn 9, Issue 1, 2007, Pages 26-35

  Poulsen, Christian ^a   Langkjær, Lotte ^a   Worsøe, Garsten ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN GLULISINE;

ACIDITY; ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; DILUTION; DRUG FORMULATION; DRUG QUALITY; DRUG STABILITY; INSULIN INFUSION; ISOELECTRIC PRECIPITATION; PH; PRECIPITATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ELECTROCHEMISTRY; INSULIN; INSULIN INFUSION SYSTEMS; PRECIPITATION;

EID: 33847206458     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.0054     Document Type: Article

References (35)

1. Zinman B: Insulin pump therapy and rapid acting insulin: what have we learned? Int J Clin Pract 2001;123:47-50.
2. Tamborlane WV, Bonfig W, Boland E: Recent advances in treatment of youth with Type 1 diabetes: better care through technology. Diabet Med 2001;18:864-870.
3. Mecklenburg RS, Guinn TS: Complications of insulin pump therapy: the effect of insulin preparation. Diabetes Care 1985;8:367-370.
4. Bode BW, Tamborlane WV, Davidson PC: Insulin pump therapy in the 21st Century: strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med 2002;111:69-77.
5. Mecklenburg RS, Benson EA, Benson JW Jr, Blumenstein BA, Fredlund PN, Guinn TS, Metz RJ, Nielsen RL: Long-term metabolic control with insulin pump therapy. Report of experience with 127 patients. N Engl J Med 1985;313:465-468.
6. Pickup J, Mattock M, Kerry S: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705-708.
7. Bruttomesso D, Pianta A, Crazzolara D, Scaldaferri E, Lora L, Guarneri G, Mongillo A, Gennaro R, Miola M, Moretti M, Confortin L, Beltramello GP, Pais M, Baritussio A, Casiglia E, Tiengo A: Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med 2002;19:628-634.
8. Plotnick LP, Clark LM, Brancati FL, Erlinger T: Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003;26:1142-1146.
9. Eichner HL, Selam JL, Woertz LL, Cornblath M, Charles MA: Improved metabolic control of diabetes with reduction of occlusions during continuous subcutaneous insulin infusion. Diabetes Nutr Metab Clin Exp 1988;1:283-287.
10. Pickup J, Keen H: Continuous subcutaneous insulin infusion at 25 years-evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25:593-598.
11. Joseph JI, Torjman MC: The Artificial Pancreas Symposium: glucose monitoring, insulin delivery, feedback control. Diabetes Technol Ther 1999;1:323-328.
12. Brange J, Owens DR, Kang S, Vølund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923-954.
13. Zinman B, Tildesley H, Chiasson J, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-443.
14. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R: Use of insulin lispro in continuous subcutaneous insulin infusion treatment-results of a multicenter trial. Diabetes Care 1999;22:784-788.
15. Bode BW, Strange P: Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001;24:69-72.
16. Bode BW, Raskin P, Weinstein R, Davidson J, Bell D, Henry R, McGill J, Huang WC, Nadeau D, Reinhardt RR: Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion-a randomized study in type 1 diabetes. Diabetes Care 2002;25:439-444.
17. Colquitt J, Royle P, Waugh N: Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003;20:863-866.
18. Radermecker RP, Scheen AJ: Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004;20:178-188.
19. Lougheed WD, Woulfe-Flanagan H, Clement JR, Albisser AM: Insulin aggregation in artificial delivery systems. Diabetologia 1980;19:1-9.
20. Owens DR, Zinman B, Bolli GB: Insulins today and beyond. Lancet 2001;358:739-746.
21. Poulsen C, Langkjær L, Worsøe C: Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther 2005;7:142-150.
22. Brange J, Skelbaek-Pedersen B, Langkjær L, Damgaard U, Ege H, Havelund S, Heding LG, Jørgensen KH, Lykkeberg J, Markussen J, Pingel M: Galenics of Insulin. The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations. Berlin: Springer-Verlag, 1987.
23. The European Pharmacopoeia Forum, Strasbourg, European Directorate for the Quality of Medicines: Insulin aspart-insulinum aspartum. Pharmeuropa 2003;15:148-151.
24. Apidra-Scientific Discussion (EMEA). http://www.emea.eu.int/humandocs/ Humans/EPAR/apidra/apidra.htm 2005 (accessed November 15, 2005).
25. Richards JP, Stickelmeyer MP, Flora DB, Chance RE, Frank BH, DeFelippis MR: Self-association properties of monomeric insulin analogs under formulation conditions. Pharm Res 1998;15:1434-1441.
26. Kaarsholm NC, Havelund S, Hougaard P: Ionization behavior of native and mutant insulins: pK perturbation of B13-Glu in aggregated species. Arch Biochem Biophys 1990;283:496-502.
27. Whittingham JL, Edwards DJ, Antson AA, Clarkson JM, Dodson GG: Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 Pro → Asp insulin analogues. Biochemistry 1998;37:11516-11523.
28. Rahuel-Clermont S, French CA, Kaarsholm NC, Dunn MF: Mechanisms of stabilization of the insulin hexamer through allosteric ligand interactions. Biochemistry 1997;36:5837-5845.
29. Wright AWD, Little JA: Cannula occlusion with use of insulin lispro and insulin infusion system. Diabetes Care 1998;21:874.
30. Wolpert HA, Faradji RN, Bonner-Weir S, Lipes MA: Drug points: metabolic decompensation in pump users due to lispro insulin precipitation. BMJ 2002;324:1253.
31. Hanaire-Broutin H, Schumicki DM, Hoogma RPLM, Souhami E: Safety of insulin glulisine compared with insulin aspart administered by continuous subcutaneous insulin infusion (CSII) [abstract]. Diabetes 2004;53(Suppl 2):15-OR.
32. Melberg SG, Havelund S, Villumsen J, Brange J: Insulin compatibility with polymer materials used in external pump infusion systems. Diabet Med 1988;5:243-247.
33. Punnia-Moorthy A: Evaluation of pH changes in inflammation of the subcutaneous air pouch lining in the rat, induced by carrageenan, dextran and Staphylococcus aureus. J Oral Pathol 1987;16:36-44.
34. Bryant RE, Rashad AL, Mazza JA, Hammond D: Beta-lactamase activity in human pus. J Infect Dis 1980;142:594-601.
35. Lenhard MJ, Reeves GD: Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001;161:2293-2300.